WHO bases its recommendations on surveillance data collected through the Global Influenza Surveillance and Response System (GISRS), supported by collaborating centres and essential regulatory laboratories.
The pharmaceutical giant will pay USD221.50 per share in cash to purchase the US biotech company, which has developed an innovative platform called drug-Fc conjugates (DFCs).